Sodium-dependent phosphate transport protein 2B (NaPi2b) is a protein that in humans is encoded by the SLC34A2 gene.
Clinical significance Sodium-dependent phosphate transport protein 2b (NaPi2b) is a tumor-associated antigen. upifitamab rilsodotin, an antibody-drug conjugate (ADC) targeting NaPi2b, was evaluated in Phase 3 clinical trials for recurrent platinum-sensitive ovarian cancer. The trials were, however, terminated in September of 2023 by the sponsor.
See also Solute carrier family Pulmonary alveolar microlithiasis
References
Further reading






